Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06785012 · ClinicalTrials.gov registry record · Phase 2
A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder
A Phase 2 study of Depressive Disorder, Major, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 124
- Enrollment target
- 20
- Study locations
NCT06785012 is a Phase 2 study of Depressive Disorder, Major that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 124 participants, below the 240-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (48% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT06785012, a Phase 2 study of Depressive Disorder, Major, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 124 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate how well JNJ-89495120 works (anti-depressant effects) and how well it is tolerated as compared to placebo on reducing the symptoms of depression in participants with major depressive disorder (MDD).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG JNJ-89495120
Study Locations (20)
California
- CI Trials - Bellflower
- Wake Research PRI Encino - Encino
- National Institute Of Clinical Research - Garden Grove
- WR-Newport Beach - Newport Beach
- ATP Clinical Research - Orange
- Anderson Clinical Research - Redlands
- Artemis Institute for Clinical Research - San Diego
- Lumos Clinical Research Center LLC - San Jose
- Syrentis Clinical Research - Santa Ana
- Inland Psychiatric Medical Group Inc - Temecula
- Sunwise Clinical Research - Walnut Creek
Arizona
- Chandler Clinical Trials - Chandler
- IMA Clinical Research PC Phoenix - Phoenix
- Noble Clinical Research - Tucson
- University of Arizona - Tucson
Florida
- Gulfcoast Medical Research Center - Fort Myers
- The Medici Medical Research - Hollywood
- Advanced Research Institute of Miami - Homestead
Alabama
- UAB Huntsville Regional Medical Campus - Huntsville
Colorado
- Mountain View Clinical Research - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2024-12-26 |
| Est. Completion | 2026-06-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06785012
The ClinicalTrials.gov registry entry for NCT06785012 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 240-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (48% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Depressive Disorder, Major appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06785012 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT06785012 about?
NCT06785012 is a clinical study titled "A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder". The purpose of this study is to evaluate how well JNJ-89495120 works (anti-depressant effects) and how well it is tolerated as compared to placebo on reducing the symptoms of depression in participants with major depressive disorder (MDD).
What is the current status of trial NCT06785012?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2024-12-26. Estimated completion is 2026-06-26.
What conditions does trial NCT06785012 study?
This clinical trial studies the following conditions: Depressive Disorder, Major.
What interventions are being tested in trial NCT06785012?
The interventions under investigation include: Placebo (DRUG), JNJ-89495120 (DRUG).
Who is sponsoring clinical trial NCT06785012?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06785012 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depressive Disorder, Major
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab
RECRUITING · Phase 2
-
Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation
RECRUITING · Phase 2
-
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
RECRUITING · Phase 2
-
Individualized Functional Connectivity Targeting in aiTBS for Depression
ACTIVE NOT RECRUITING · Phase 2
-
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
COMPLETED · Phase 2
-
A Safety, Efficacy and Tolerability Study of SEP-225289
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.